Payment overview · 2025
General Payments
$49.06
3 reported records · 2 companies
Healthcare provider profile · identity verified
Ara Shafrazian
Allopathic & Osteopathic Physicians|Family Medicine · GLENDALE, CA · NPI 1053706234
Verified facts
What the public records show
CMS Open Payments records show Ara Shafrazian received $49.06 in general payments during 2025 across 3 reported records.
Amgen Inc. accounted for 69.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Prolia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.05 | 69.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.01 | 30.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $49.06 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.05 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
66 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
15 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 458 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 393 | 81 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 265 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 263 | 49 |
| Omeprazole | Omeprazole | 260 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 234 | 45 |
| Losartan Potassium | Losartan Potassium | 233 | 44 |
| Metformin Hcl | Metformin Hcl | 215 | 44 |
| Gabapentin | Gabapentin | 193 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 179 | 39 |
| Montelukast Sodium | Montelukast Sodium | 175 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 166 | 40 |
| Diclofenac Sodium | Diclofenac Sodium | 140 | 31 |
| Trazodone Hcl | Trazodone Hcl | 137 | 27 |
| Ibuprofen | Ibuprofen | 131 | 27 |
| Carvedilol | Carvedilol | 127 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 123 | 22 |
| Jardiance | Empagliflozin | 122 | 21 |
| Simvastatin | Simvastatin | 107 | 22 |
| Donepezil Hcl | Donepezil Hcl | 106 | 19 |
| Lisinopril | Lisinopril | 105 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 21 |
| Eliquis | Apixaban | 99 | 19 |
| Furosemide | Furosemide | 96 | 30 |
| Ozempic | Semaglutide | 95 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 93 | 22 |
| Vascepa | Icosapent Ethyl | 93 | 19 |
| Finasteride | Finasteride | 80 | 15 |
| Icosapent Ethyl | Icosapent Ethyl | 79 | 19 |
| Mounjaro | Tirzepatide | 79 | 15 |
| Naproxen | Naproxen | 78 | 20 |
| Azithromycin | Azithromycin | 75 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 18 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 73 | 17 |
| Alprazolam | Alprazolam | 72 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 20 |
| Famotidine | Famotidine | 70 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 69 | 19 |
| Xarelto | Rivaroxaban | 67 | 12 |
| Linzess | Linaclotide | 66 | 13 |
| Myrbetriq | Mirabegron | 66 | 12 |
| Allopurinol | Allopurinol | 62 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 58 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 57 | 16 |
| Sertraline Hcl | Sertraline Hcl | 57 | 15 |
| Ezetimibe | Ezetimibe | 56 | 11 |
| Januvia | Sitagliptin Phosphate | 56 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 55 | suppressed |
| Nifedipine Er | Nifedipine | 52 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 51 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 51 | 14 |
| Glimepiride | Glimepiride | 49 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 46 | suppressed |
| Clonazepam | Clonazepam | 46 | suppressed |
| Bupropion Xl | Bupropion Hcl | 45 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | suppressed |
| Lorazepam | Lorazepam | 40 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 39 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 29 |
| Baclofen | Baclofen | 37 | suppressed |
| Lactulose | Lactulose | 37 | 16 |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 37 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 35 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Rytary | Carbidopa/Levodopa | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Olanzapine | Olanzapine | 28 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 19 |
| Mupirocin | Mupirocin | 26 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Meloxicam | Meloxicam | 23 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Procto-Med Hc | Hydrocortisone | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Tavaborole | Tavaborole | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 15 |
| Dutasteride | Dutasteride | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Prolia | Denosumab | 15 | 11 |
| Trulicity | Dulaglutide | 15 | suppressed |
| Fluocinonide | Fluocinonide | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Sure Comfort | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $49.06 · 3 records | Amgen Inc. | CREON, LINZESS, OTEZLA, REPATHA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error